Mississauga, ON -- (SBWire) -- 12/09/2013 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Senseco Releases Optimistic Data from Third Cohort in Blood Cancer Clinical Trial.”
Companies mentioned in this article include Senesco Technologies, Inc. (OTCQB:SNTI) and Celgene (Nasdaq:CELG).
Article Excerpt:
Lymphona is the most common type of blood cancer, occurring when lymphocytes, a type of white blood cell, multiply and grow uncontrollably. There are two main types of lymphocytes, B-cells and T-cells, which can develop into one of two primary types of lymphoma, Hodgkin and non-Hodgkin, and spread to various parts of the body. The most common form of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma, accounting for nearly one-third of newly diagnosed NHL cases. In the United States alone, there are about 120,000 cases of diffuse large B-cell lymphoma.
Blood-borne cancers are the focus of Senesco Technologies, Inc. (OTCQB:SNTI) with its flagship therapeutic SNS01-T. The company’s gene regulation technology is comprised of three components: a DNA plasmid, a small inhibitory RNA (siRNA) and polyethylenimine, which cumulatively work to target damaged cancerous cells and destroy them.
Pre-clinical research showed SNS01-T combined with Celgene’s (Nasdaq:CELG) lenalidomide (Revlimid) outperformed lenalidomide alone in mouse models of multiple myeloma. Lenalidomide is a derivative of thalidomide that is commonly used to treat blood cancers. In the study, implanted myeloma tumors were eradicated after a single six-week dose cycle of the combination in 67 percent of the mice, with no regrowth after two months without treatment. All the mice in the study lived 102 days to the conclusion of the trial.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/413/senseco-releases-optimistic-data-from-third-cohort-in-blood-cancer-clinical-trial.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
All Penny Stocks.com News: Senseco Releases Optimistic Data from Third Cohort in Blood Cancer Clinical Trial